Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a four-week randomized controlled single blinded trial of subjects presenting with
resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly
assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to
routine intensification of antihypertensive regimen , all added to previous regimen with
unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four
following add-on therapy initiation. The primary outcome is change in office and
self-measurement blood pressure recorded at each visit, and secondary outcomes are variations
in serum potassium, sodium, and creatinine levels.